Gilgamesh Pharmaceuticals, Inc.

Founded in 2019, Gilgamesh Pharmaceuticals focuses on creating new chemical entities (NCEs) aimed at curing psychiatric disorders. In March 2026, Gilgamesh Pharmaceuticals, Inc. raised USD 60 million in series A funding led by led by Satori Capital, with participation from Prime Movers Lab. Other unspecified investors also participated in the round.

The leadership team includes co-founders Dalibor Sames, Jonathan Sporn (CEO), and Andrew Kruegel (CSO). Gilgamesh Pharmaceuticals specializes in developing innovative new chemical entities (NCEs) aimed at transforming the treatment landscape for psychiatric disorders. Their core product offerings focus on rapid-acting therapies designed to address conditions such as depression, anxiety, and opioid use disorder. These therapeutics are characterized by their oral bioavailability, optimized duration of effect, and improved safety profiles, particularly with fewer dissociative effects compared to existing treatments.

Targeting both clinicians and patients, Gilgamesh's products are intended for markets primarily in North America and Europe, where there is a significant demand for advanced mental health solutions that move beyond traditional symptom management. The company's commitment to collaboration with pharmaceutical partners and research institutions bolsters its position in the biotech sector, emphasizing its role in pioneering effective therapies. Gilgamesh Pharmaceuticals operates through a transaction structure that includes partnerships with pharmaceutical companies and research institutions, facilitating the development and distribution of its products. Revenue generation is driven by milestone payments, licensing agreements, and potential royalties from successful product launches.

While specific pricing plans for their flagship products are not disclosed, the company’s focus on providing rapid and sustained efficacy in its offerings underscores its strategic positioning within the mental health market.